Status:
RECRUITING
Cycle-Length Mapping in Patients With Non-paroxysmal Atrial Fibrillation
Lead Sponsor:
Ting-Yung Chang
Conditions:
Atrial Fibrillation (AF)
Eligibility:
All Genders
20+ years
Brief Summary
The critical atrial substrates in maintaining persistent atrial fibrillation might be identified by Cycle-Length Mapping (CLM) module. Based on the results of multicenter study in Cycle-Length Mapping...
Eligibility Criteria
Inclusion
- Patients who sign the informed consent forms, and allow to be followed.
- Symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication.
- Patients with persistent/permanent AF (sustained beyond seven days, or lasting less than seven days but necessitating pharmacologic or electrical cardioversion). Persistent AF is defined as an AF episode which lasts longer than 7 days, Persistent AF which lasted longer than 12 months will be defined as long standing persistent AF.
- Patients with age equal or greater than 20 years old regardless of gender.
Exclusion
- The presence of an atrial or ventricular thrombus.
- Patients who are allergic to or unsuitable for use with the contrast media.
- Pregnant patients or patients who are unavailable to receive X-ray.
- Patients with severe renal insufficiency. (Glomerular Filtration Rate \[GFR\] \< 15 mg/dl or under dialysis)
- Patients had autonomic nervous system disorder (e.g. respiratory apnea).
- Patients with age less than 20 years old or greater than 90 years old regardless of gender.
- Contraindications to anticoagulation.
Key Trial Info
Start Date :
August 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06960252
Start Date
August 1 2025
End Date
December 31 2027
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Outside US, Taiwan, 112